At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 200 enrolled
Drug / intervention
MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tabletdrug
Likely dose
MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatment of Osteoporosis in Postmenopausal Women and Men
In Brief
A Phase 3 clinical trial evaluating MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet for Osteoporosis. Completed, enrolled 200 participants.
Detailed Summary
This study will assess the effect of 26 weeks of once-weekly treatment with MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) on serum levels of 25-hydroxyvitamin D \[25(OH)D\].
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartOct 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedSep 20, 2011
Enrollment StartOct 26, 2011
Primary CompletionDec 5, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.8 years ago
Interventions
MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tabletdrug
One combination tablet orally once a week